Srivastava K C
Department of Environmental Medicine, Odense University, Denmark.
Prostaglandins Leukot Med. 1987 Sep;29(1):79-84. doi: 10.1016/0262-1746(87)90099-0.
The effects of four beta-adrenoceptor blocking agents on platelet aggregation, formation of thromboxane from exogenous arachidonic acid (AA) in platelets, on AA incorporation in platelet phospholipids, and on platelet phospholipase activity were studied. Of the four drugs pindolol inhibited thromboxane formation in a dose-related (0.25-1.0 mM) manner apparently by exerting its influence at the cyclooxygenase (CO) level. This drug also inhibited aggregation induced by AA, collagen, epinephrine and ADP. Atenolol and metoprolol though not showing inhibition of AA-induced aggregation did inhibit collagen- and ADP-induced aggregation; metoprolol reversed ADP-induced aggregation, and abolished second phase of epinephrine-induced aggregation. Timolol did not inhibit aggregation induced by all the aggregating agents. Atenolol inhibited (by ca. 10%) TxB2 formation in platelets from exogenous as well as endogenous AA at rather high concentrations (1.0 mM). Metoprolol and timolol did not do so. The observations reported here can be best explained by taking into account the membrane stabilizing effects and lipophilic properties of the drugs.
研究了四种β-肾上腺素受体阻滞剂对血小板聚集、血小板中由外源性花生四烯酸(AA)生成血栓素、AA掺入血小板磷脂以及血小板磷脂酶活性的影响。在这四种药物中,吲哚洛尔以剂量相关(0.25 - 1.0 mM)的方式抑制血栓素的形成,显然是通过在环氧化酶(CO)水平发挥作用。该药物还抑制由AA、胶原、肾上腺素和ADP诱导的聚集。阿替洛尔和美托洛尔虽然不抑制AA诱导的聚集,但确实抑制胶原和ADP诱导的聚集;美托洛尔逆转ADP诱导的聚集,并消除肾上腺素诱导聚集的第二阶段。噻吗洛尔不抑制所有聚集剂诱导的聚集。阿替洛尔在相当高的浓度(1.0 mM)下抑制外源性以及内源性AA在血小板中生成TxB2(约10%)。美托洛尔和噻吗洛尔则无此作用。综合考虑药物的膜稳定作用和亲脂性,可以最好地解释此处报告的观察结果。